Cancer Victims Fight Bayer's Landmark Roundup Deal

A significant legal challenge has emerged against Bayer's proposed $7.25 billion class action settlement addressing claims from users of its glyphosate-based weed-killing products who have developed non-Hodgkin lymphoma (NHL). A coalition of 14 law firms, representing nearly 20,000 plaintiffs, has filed motions to intervene and extend the preliminary approval timeline in St. Louis.

These firms argue that the settlement, negotiated by a different group of plaintiffs' lawyers, grants Bayer and its parent company, Bayer AG, a broad release of liability while potentially offering inadequate compensation to many class members. They highlight concerns that the deal heavily favors occupational users over residential users, with proposed payments varying significantly based on diagnosis age and user type.